IFNA1 and colorectal carcinoma: Thus, on the basis of the overall preclinical and clinical data on IFN-DC obtained by our group [69,70,71,72,89,90], we consider these DC as valuable autologous cell products for the development of new-generation DC products to be used in clinical trials in CRC patients.